Geoffrey Uy, MD
Enriched profileProfessor of Medicine, Division of Oncology; Medical Director for Clinical Research · Washington University School of Medicine
Geoffrey Uy is Professor of Medicine, Division of Oncology; Medical Director for Clinical Research at Washington University School of Medicine. OpenAlex indexes 469 publications with 14,866 citations (h-index 56); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 21 Oct 2026
Geoffrey Uy, MD, is Professor of Medicine, Division of Oncology at Washington University School of Medicine. The public record shows 469 publications with 14,866 citations (h-index 56), centered on Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 13 companies, 4 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · American journal of hematology
- Top research focus: Acute Myeloid Leukemia Research
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 21 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 164.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 21 Oct 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Sponsor: Washington University School of Medicine
Industry payments
Updated 21 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20258 payments
- Geron CorporationProgram year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
76%Other antiemetics65.8%Fosaprepitant100%Part B, office-administered≥13 patientsSerotonin-3 Receptor Antagonist8.8%Palonosetron hcl94%Ondansetron Hcl3%Ondansetron Odt3%Part D + Part B<11 patients+ 3 more classes in this area
Sensory organs
13.6%Corticosteroid12.9%Dexamethasone sodium phosphate100%Part B, office-administered≥31 patientsFluoroquinolone Antibacterial0.7%Ciprofloxacin Hcl100%Part D≥13 patientsAnti-infectives
4.6%Azole Antifungal1.4%Fluconazole100%Part D≥16 patientsShort-acting sulfonamides1.2%Sulfamethoxazole-Trimethoprim100%Part D≥12 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 21 Oct 2026
4 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
Congress activity
Updated 21 Oct 2026
130 congress contributions (2007–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- A prospective Study of whole genome sequencing for genomic profiling and risk determination in MDS
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 21 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
American journal of hematology
Article2026 - Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.
Blood advances
Clinical Trial2026 - Oral Azacitidine Maintenance After CPX-351 in Transplant-Ineligible Patients With Therapy-Related or Myelodysplasia-Related Acute Myeloid Leukemia.
American journal of hematology
Letter2026
Most-cited works
by citation count (OpenAlex)- 01Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLArticle1,454 citations2018
- 02
- 03TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesArticle791 citations2016
- 04
- 05
Network
Updated 21 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 21 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Editorial & leadership roles
journal and society appointments- Co-Chair
Leukemia Committee, Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Member
National Comprehensive Cancer Center Network Acute Lymphoblastic Leukemia Guideline Panel
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Member
NCI Leukemia Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - Special Government Employee
FDA Oncologic Drugs Advisory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
John Dipersio, MD
Washington University School of Medicine
Douglas Mann, MD
Washington University School of Medicine
Nancy Bartlett, MD
Washington University School of Medicine
Cynthia Ma, MD
Washington University School of Medicine
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center